Nterests.Authors’ ContributionsJun Han, Hang-Hang Xu, Xiao-Long Chen, Hao-Ran Hu, and Kun-Mei Hu Performed the experiments and analyze data. Jun Han and Guo-Wei He wrote up the manuscript. Jun Han and Zhi-Wu Chen developed the protocol and discussion around the final results. Guo-Wei He contributed to critical discussion around the study design and style, results, presentation, writing up, and submission.AcknowledgmentsThe authors appreciated the contributions from the other members of our laboratory: ZL QIN, H YU, FY FAN, and XW LI. This study was supported by the National Organic Science Foundation of China beneath Grant no. 81173596; the All-natural Science Foundation on the Department of Education of Anhui province under Grant no. KJ2015A157. This study was supported by an unrestricted grant from Recordati SpA.AbbreviationACh: BCA: CIR: CBA: EDHF: EEG: GAPDH: IR: PGI2 : NO: PSS: RR: SD rats: TRP: TRPV: TFR: Acetylcholine Bicinchoninic acid Cerebral ischemia-reperfusion Cerebral basal artery Endothelium-dependent hyperpolarizing element Electroencephalograph Glyceraldehyde 3-phosphate dehydrogenase Ischemia/reperfusion injury Prostacyclin Nitric oxide Precooled physiological salt solution Ruthenium red Sprague-Dawley rats Transient receptor possible TRP vanilloid channel Total flavonoids of Rhododendron.
Rheumatoid arthritis (RA) is a chronic, systemic, and Cefazedone Inhibitor autoimmune illness. It might lead to irreversible joint destruction and deformity, seriously affecting people’s high-quality of life [1]. Disease-modifying antirheumatic drugs, anti-inflammatory drugs, and painkillers have extended been applied to treat RA [2]. With the development of medicine, a growing number of attention is paid to diverse therapeutic strategies, as well as a quantity of individuals pick adjuvant therapies and complementary and option medicine to treat their RA. As a crucial component of complementary and option medicine, Zhuang medicine plays an important function in treating RA. Longzuan Tongbi Formula (LZTB) is an powerful proven prescription in Zhuang medicine for treating active RA. It consists of Toddalia asiatica (TA), Kadsura coccinea (KC), Alangium chinense (AC), Sinomenium acutum (SA), Bauhinia championii (BC), Spatholobus suberectus (SS), Zanthoxylum nitidum (ZN), and Ficus hirta Vahl (FHV). Clinical studies have shown that LZTB can substantially lower RA patients’ erythrocyte sedimentation price, and that it has a good therapeutic effect on improving RA patients’ morning stiffnessand joint pain [3]. Having said that, its active components, underlying targets, and pharmacological mechanism in treating RA are nevertheless not clear. 714272-27-2 Data Sheet Compound preparations in standard medicine can act on multiple targets by means of multicomponent reaction, play an indispensable role in core pathways in diseases, and help achieve the objective of treating diseases [4]. Considerably interest has been given to the study in the multicomponent and multitarget action mechanism. With the rapid development of bioinformatics, network pharmacology has turn into a new method to correctly and systematically study the mechanism of action, security, and other elements of compound preparations in regular medicine [5]. For example, Tang et al. have applied network pharmacology to study the mechanism of action of XuanHuSuo Powder in treating osteoarthritis [8], Liu et al. have adopted a network pharmacology strategy in exploring the pharmacological mechanism of Xiaoyao Powder on anovulatory infertility [9], and Li et al. have analyzed the therapeutic effects of Zi Dian.
